-+ 0.00%
-+ 0.00%
-+ 0.00%

IMMUNEERING TO ANNOUNCE 12-MONTH OVERALL SURVIVAL DATA FROM PHASE 2A CLINICAL TRIAL OF ATEBIMETINIB + MGNP IN FIRST-LINE PANCREATIC CANCER PATIENTS ON JANUARY 7, 2026

Reuters·12/23/2025 13:00:03

Please log in to view news